LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Deschisă

3.56 9.2

Rezumat

Modificarea prețului

24h

Curent

Minim

3.24

Maxim

3.6

Indicatori cheie

By Trading Economics

Venit

1.9M

-68M

Vânzări

-5.8M

42M

Marjă de profit

-163.26

Angajați

570

EBITDA

25M

-41M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+38.46% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

60M

1.1B

Deschiderea anterioară

-5.64

Închiderea anterioară

3.56

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 nov. 2025, 21:34 UTC

Câștiguri

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov. 2025, 23:42 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q EPS 52c >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q Sales $22.6B >JBS

13 nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov. 2025, 22:02 UTC

Câștiguri

Nu Holdings 3Q Net $783M >NU

13 nov. 2025, 22:01 UTC

Câștiguri

Nu Holdings 3Q Rev $4.2B >NU

13 nov. 2025, 21:51 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov. 2025, 21:50 UTC

Câștiguri

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov. 2025, 21:41 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov. 2025, 21:33 UTC

Câștiguri

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov. 2025, 21:31 UTC

Câștiguri

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov. 2025, 21:23 UTC

Câștiguri

Intchains Group 3Q Rev $1.3M >ICG

13 nov. 2025, 21:03 UTC

Câștiguri

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov. 2025, 21:02 UTC

Câștiguri

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Rev $6.8B >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparație

Modificare preț

Maravai LifeSciences Holdings Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

38.46% sus

Prognoză pe 12 luni

Medie 4.5 USD  38.46%

Maxim 5 USD

Minim 4 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMaravai LifeSciences Holdings Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

3

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.02 / 2.115Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat